Journal of Clinical Oncology
Articles in this Issue
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma.
e19578 Background: The presence of multiple MRI focal lesions is a key diagnostic criterion for multiple myeloma (MM). Some patients with smoldering multi...
Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis.
2642 Background: PD-1, PD-L1, and CTLA-4 blockade are standard therapies in multiple solid tumors, and novel agents targeting alternative co-stimulatory a...
A therapeutic vaccine for fibrolamellar hepatocellular carcinoma.
2503 Background: Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer affecting children and young adults that is driven by a chime...
Adjuvant therapy in small intestinal leiomyosarcoma: A comparative analysis of outcomes.
e23556 Background: Leiomyosarcoma of the small intestine is a rare gastrointestinal cancer that has been sparsely studied compared to other intraabdominal...
Real-world observational study of fruquintinib in combination with irinotecan and capecitabine as second-line treatment in patients with advanced colorectal cancer.
e15539 Background: To improve outcomes for patients with advanced colorectal cancer, chemotherapy can be combined with anti-VEGF and anti-EGFR agents. Thi...
Identifying unmet cancer survivor needs in a background of comprehensive and free health care: A cross-sectional study from India.
e24064 Background: Very limited data exists on identifying the unmet needs of cancer survivors in the Indian subcontinent, with no studies in the backgrou...
A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors.
TPS3163 Background: MesoC2 (PF-08052666) is an ADC that targets mesothelin (MSLN), a cell-surface glycoprotein overexpressed in solid tumors including mes...
Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis.
e19538 Background: Patients with multiple myeloma (MM) and type 2 diabetes mellitus (T2DM) experience increased risks of m...
Optimizing immunotherapy for advanced gastric and gastroesophageal junction cancer: A modelling cost-effectiveness study.
e23113 Background: The optimal use of programmed death-ligand 1 (PD-L1) expression to guide immunotherapy in advanced gastric or gastroesophageal junction...
Retlirafusp alfa-a bifunctional anti-PD-L1/TGF-βRII agent plus nab-paclitaxel and carboplatin in pre-treated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, phase II clinical trial.
6029 Background: Treatment for pre-treated patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an important unme...
Clinical outcomes for patients with hyperlipidemia and early-onset breast cancer: An analysis of the National Inpatient Sample.
11184 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing gl...
Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma.
e24116 Background: CD20 x CD3 bispecific antibody therapies (BsAbs) are currently approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL...
Race and correlates of cancer cachexia in the Detroit Research on Cancer Survivors cohort.
12094 Background: Cancer cachexia is a multifunctional syndrome characterized by the ongoing loss of skeletal muscle mass that cannot be fully reversed by...
Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC).
e19027 Background: The efficacy of continuous zanubrutinib (zanu) has been evaluated in the SEQUOIA study (NCT03336333) in TN CLL/SLL, while the combinati...
Clinical outcomes of prompt versus deferred <sup>177</sup> Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: A real-world prostate cancer disease observation (PRECISION) data platform analysis.
e17030 Background: The broad therapeutic arsenal for mCRPC, with overlapping indications, makes selecting the optimal treatment sequence challenging in cl...
Impact of 2021 United States cancer screening guideline changes on racial and ethnic differences in patient-reported adherence to age-appropriate colorectal cancer screening.
10546 Background: In 2021, the US Preventive Services Task Force and the US Multi-Society Task Force on Colorectal Cancer updated screening guidelines to...
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
1007 Background: DHP107 is a novel oral formulation of paclitaxel that is approved in South Korea and China for the treatment of gastric cancer. DHP107 ha...
A phase II biomarker RCT in women at high risk for breast cancer: Low dose tamoxifen and lifestyle changes for breast cancer prevention (TOLERANT study).
TPS10625 Background: Breast cancer (BC) prevention in high-risk women is crucial. Tamoxifen, despite its efficacy, has limited use due to its side effects...
Sequential chemo-immunotherapy as a novel bridging strategy for non-complete responders after neoadjuvant chemoradiotherapy in esophageal cancer: First prospective phase 2 trial challenging the immediate-surgery paradigm.
4066 Background: Locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients with non-clinical complete response (non-CCR) after neoadjuvant ch...
Survival analysis, and racial and gender disparities in adult T-cell leukemia/lymphoma: A population based retrospective study.
e22571 Background: Adult T cell leukemia/lymphoma (ATLL) is a rare and aggressive T cell malignancy, associated with human T cell lymphotropic virus 1 (HT...
Real-world analyses of first-line immune checkpoint inhibitors in unresectable Merkel cell carcinoma.
e21597 Background: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer of the elderly. Immune checkpoint inhibitors (ICI) are now...
Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US).
5041 Background: Prior studies suggest that chemotherapy-naïve pts with mCRPC treated with AA have a higher CV event-related hospitalization risk than tho...
Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2− early breast cancer (EBC) eligible for NATALEE.
527 Background: The NATALEE trial showed statistically significant and clinically meaningful invasive disease–free survival benefit with ribociclib + nons...
Blended survivorship and palliative care for patients with advanced lung cancer receiving targeted therapy: An open pilot.
1634 Background: Targeted therapy improves survival and quality of life for patients with advanced non-small cell lung cancer (NSCLC) with driver alterati...
Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
e17592 Background: Oregovomab is a murine monoclonal antibody directed to the tumor-associated antigen CA125 that stimulate host cellular and humoral immu...